Researchers reported that two simple blood-derived inflammation scores—systemic immune-inflammation index (SII) and systemic inflammatory marker calculations based on complete blood counts—may predict survival and metastatic spread risk in vulvar cancer. The study analyzed systemic markers to improve how clinicians anticipate disease behavior before surgery. Presented in a GeroScience context, the work suggests that inexpensive, routine lab data could support earlier risk stratification, potentially guiding intensity of treatment planning. The approach leverages widely available hematology measurements rather than requiring advanced molecular testing. The finding matters because vulvar cancer management often depends on how aggressively the disease is expected to behave, and pre-operative biomarkers can help reduce uncertainty when surgical decisions are being made. The study also reflects continued interest in inflammation biology as a practical prognostic lens in solid tumors.